---
document_datetime: 2025-11-23 08:09:09
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/dyrupeg-0.html
document_name: dyrupeg-0.html
version: success
processing_time: 0.1230245
conversion_datetime: 2025-12-27 17:46:20.335501
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Dyrupeg

[RSS](/en/individual-human-medicine.xml/254530)

##### Authorised

This medicine is authorised for use in the European Union

pegfilgrastim

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Dyrupeg](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-76101)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Dyrupeg is a medicine used in patients with cancer to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections.

It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (neutropenia accompanied by fever) in patients treated with cytotoxic chemotherapy (a type of cancer treatment that kills cancer cells).

Dyrupeg is not intended for use in patients with the blood cancer chronic myeloid leukaemia or with myelodysplastic syndromes (conditions in which large numbers of abnormal blood cells are produced, which can develop into leukaemia).

Dyrupeg contains the active substance pegfilgrastim and is a biological medicine. It is a 'biosimilar medicine'; this means that Dyrupeg is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the European Union (EU). The reference medicine for Dyrupeg is Neulasta. For more information on biosimilar medicines, see [here](https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines) .

Expand section

Collapse section

## How is Dyrupeg used?

Dyrupeg can only be obtained with a prescription, and treatment should be started and supervised by a doctor who has experience in the treatment of cancer or blood disorders.

It is available as a prefilled syringe and is given as a single injection under the skin, at least 24 hours after the end of each cycle of chemotherapy. Patients can inject themselves if they have been trained appropriately.

For more information about using Dyrupeg, see the package leaflet or contact your doctor or pharmacist.

## How does Dyrupeg work?

The active substance in Dyrupeg, pegfilgrastim, is a form of filgrastim, which is very similar to a human protein called granulocyte colony stimulating factor (G-CSF). Filgrastim works by encouraging the bone marrow to produce more white blood cells, increasing white blood cell counts and so treating neutropenia.

Filgrastim has been available in other medicines in the EU for a number of years. In Dyrupeg, filgrastim has been 'pegylated' (attached to a chemical called polyethylene glycol). This slows down the removal of filgrastim from the body, allowing the medicine to be given less often.

## What benefits of Dyrupeg have been shown in studies?

Laboratory studies comparing Dyrupeg with Neulasta have shown that the active substance in Dyrupeg is highly similar to that in Neulasta in terms of structure, purity and biological activity. Studies have also shown that giving Dyrupeg produces similar levels of the active substance in the body to those seen with Neulasta.

Because Dyrupeg is a biosimilar medicine, the studies on the effectiveness and safety of pegfilgrastim carried out with Neulasta do not all need to be repeated for Dyrupeg.

## What are the risks associated with Dyrupeg?

The safety of Dyrupeg has been evaluated and, on the basis of all the studies carried out, the side effects of the medicine are considered to be comparable to those of the reference medicine, Neulasta.

For the complete list of side effects and restrictions of Dyrupeg, see the package leaflet.

The most common side effect with Dyrupeg (which may affect more than 1 in 10 people) is pain in the bones. Pain in muscles may occur in up to 1 in 10 people.

## Why is Dyrupeg authorised in the EU?

The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Dyrupeg has a highly similar structure, purity and biological activity to Neulasta and is distributed in the body in the same way.

The available data were considered sufficient to conclude that Dyrupeg will have the same effects as Neulasta in its authorised uses. Therefore, the Agency's view was that, as for Neulasta, the benefits of Dyrupeg outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Dyrupeg?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Dyrupeg have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Dyrupeg are continuously monitored. Suspected side effects reported with Dyrupeg are carefully evaluated and any necessary action taken to protect patients.

## Other information about Dyrupeg

Dyrupeg received a marketing authorisation valid throughout the EU on 28 March 2025.

Dyrupeg : EPAR - Medicine overview

Reference Number: EMA/46634/2025

English (EN) (110.88 KB - PDF)

**First published:** 16/04/2025

[View](/en/documents/overview/dyrupeg-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-808)

български (BG) (133.01 KB - PDF)

**First published:**

16/04/2025

[View](/bg/documents/overview/dyrupeg-epar-medicine-overview_bg.pdf)

español (ES) (109.42 KB - PDF)

**First published:**

16/04/2025

[View](/es/documents/overview/dyrupeg-epar-medicine-overview_es.pdf)

čeština (CS) (130.39 KB - PDF)

**First published:**

16/04/2025

[View](/cs/documents/overview/dyrupeg-epar-medicine-overview_cs.pdf)

dansk (DA) (107.92 KB - PDF)

**First published:**

16/04/2025

[View](/da/documents/overview/dyrupeg-epar-medicine-overview_da.pdf)

Deutsch (DE) (112.27 KB - PDF)

**First published:**

16/04/2025

[View](/de/documents/overview/dyrupeg-epar-medicine-overview_de.pdf)

eesti keel (ET) (106.98 KB - PDF)

**First published:**

16/04/2025

[View](/et/documents/overview/dyrupeg-epar-medicine-overview_et.pdf)

ελληνικά (EL) (132 KB - PDF)

**First published:**

16/04/2025

[View](/el/documents/overview/dyrupeg-epar-medicine-overview_el.pdf)

français (FR) (110.3 KB - PDF)

**First published:**

16/04/2025

[View](/fr/documents/overview/dyrupeg-epar-medicine-overview_fr.pdf)

hrvatski (HR) (130.27 KB - PDF)

**First published:**

16/04/2025

[View](/hr/documents/overview/dyrupeg-epar-medicine-overview_hr.pdf)

italiano (IT) (108.38 KB - PDF)

**First published:**

16/04/2025

[View](/it/documents/overview/dyrupeg-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (145.38 KB - PDF)

**First published:**

16/04/2025

[View](/lv/documents/overview/dyrupeg-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (129.58 KB - PDF)

**First published:**

16/04/2025

[View](/lt/documents/overview/dyrupeg-epar-medicine-overview_lt.pdf)

magyar (HU) (130.97 KB - PDF)

**First published:**

16/04/2025

[View](/hu/documents/overview/dyrupeg-epar-medicine-overview_hu.pdf)

Malti (MT) (131.91 KB - PDF)

**First published:**

16/04/2025

[View](/mt/documents/overview/dyrupeg-epar-medicine-overview_mt.pdf)

Nederlands (NL) (109.35 KB - PDF)

**First published:**

16/04/2025

[View](/nl/documents/overview/dyrupeg-epar-medicine-overview_nl.pdf)

polski (PL) (132.69 KB - PDF)

**First published:**

16/04/2025

[View](/pl/documents/overview/dyrupeg-epar-medicine-overview_pl.pdf)

português (PT) (110.94 KB - PDF)

**First published:**

16/04/2025

[View](/pt/documents/overview/dyrupeg-epar-medicine-overview_pt.pdf)

română (RO) (128.34 KB - PDF)

**First published:**

16/04/2025

[View](/ro/documents/overview/dyrupeg-epar-medicine-overview_ro.pdf)

slovenčina (SK) (131.26 KB - PDF)

**First published:**

16/04/2025

[View](/sk/documents/overview/dyrupeg-epar-medicine-overview_sk.pdf)

slovenščina (SL) (128.36 KB - PDF)

**First published:**

16/04/2025

[View](/sl/documents/overview/dyrupeg-epar-medicine-overview_sl.pdf)

Suomi (FI) (106.69 KB - PDF)

**First published:**

16/04/2025

[View](/fi/documents/overview/dyrupeg-epar-medicine-overview_fi.pdf)

svenska (SV) (106.99 KB - PDF)

**First published:**

16/04/2025

[View](/sv/documents/overview/dyrupeg-epar-medicine-overview_sv.pdf)

Dyrupeg : EPAR - Risk management plan

English (EN) (1.07 MB - PDF)

**First published:** 16/04/2025

[View](/en/documents/rmp/dyrupeg-epar-risk-management-plan_en.pdf)

## Product information

Dyrupeg : EPAR - Product information

English (EN) (629.21 KB - PDF)

**First published:** 16/04/2025

**Last updated:** 12/08/2025

[View](/en/documents/product-information/dyrupeg-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-539)

български (BG) (671.25 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/bg/documents/product-information/dyrupeg-epar-product-information_bg.pdf)

español (ES) (605.16 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/es/documents/product-information/dyrupeg-epar-product-information_es.pdf)

čeština (CS) (644.3 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/cs/documents/product-information/dyrupeg-epar-product-information_cs.pdf)

dansk (DA) (601.04 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/da/documents/product-information/dyrupeg-epar-product-information_da.pdf)

Deutsch (DE) (607.74 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/de/documents/product-information/dyrupeg-epar-product-information_de.pdf)

eesti keel (ET) (554.71 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/et/documents/product-information/dyrupeg-epar-product-information_et.pdf)

ελληνικά (EL) (681.99 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/el/documents/product-information/dyrupeg-epar-product-information_el.pdf)

français (FR) (644.21 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/fr/documents/product-information/dyrupeg-epar-product-information_fr.pdf)

hrvatski (HR) (659.34 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/hr/documents/product-information/dyrupeg-epar-product-information_hr.pdf)

íslenska (IS) (572.9 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/is/documents/product-information/dyrupeg-epar-product-information_is.pdf)

italiano (IT) (656.91 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/it/documents/product-information/dyrupeg-epar-product-information_it.pdf)

latviešu valoda (LV) (569.15 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/lv/documents/product-information/dyrupeg-epar-product-information_lv.pdf)

lietuvių kalba (LT) (587.44 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/lt/documents/product-information/dyrupeg-epar-product-information_lt.pdf)

magyar (HU) (651.49 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/hu/documents/product-information/dyrupeg-epar-product-information_hu.pdf)

Malti (MT) (704.56 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/mt/documents/product-information/dyrupeg-epar-product-information_mt.pdf)

Nederlands (NL) (582.22 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/nl/documents/product-information/dyrupeg-epar-product-information_nl.pdf)

norsk (NO) (532.86 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/no/documents/product-information/dyrupeg-epar-product-information_no.pdf)

polski (PL) (615.62 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/pl/documents/product-information/dyrupeg-epar-product-information_pl.pdf)

português (PT) (600.21 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/pt/documents/product-information/dyrupeg-epar-product-information_pt.pdf)

română (RO) (749.53 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/ro/documents/product-information/dyrupeg-epar-product-information_ro.pdf)

slovenčina (SK) (745.82 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/sk/documents/product-information/dyrupeg-epar-product-information_sk.pdf)

slovenščina (SL) (620.16 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/sl/documents/product-information/dyrupeg-epar-product-information_sl.pdf)

Suomi (FI) (531.46 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/fi/documents/product-information/dyrupeg-epar-product-information_fi.pdf)

svenska (SV) (560.9 KB - PDF)

**First published:**

16/04/2025

**Last updated:**

13/05/2025

[View](/sv/documents/product-information/dyrupeg-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000290486 11/08/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Dyrupeg : EPAR - All authorised presentations

English (EN) (47.34 KB - PDF)

**First published:** 16/04/2025

[View](/en/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-266)

български (BG) (51.01 KB - PDF)

**First published:**

16/04/2025

[View](/bg/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_bg.pdf)

español (ES) (49.44 KB - PDF)

**First published:**

16/04/2025

[View](/es/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_es.pdf)

čeština (CS) (48.17 KB - PDF)

**First published:**

16/04/2025

[View](/cs/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (49.18 KB - PDF)

**First published:**

16/04/2025

[View](/da/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (48.95 KB - PDF)

**First published:**

16/04/2025

[View](/de/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (48.6 KB - PDF)

**First published:**

16/04/2025

[View](/et/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (47.2 KB - PDF)

**First published:**

16/04/2025

[View](/el/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_el.pdf)

français (FR) (47.74 KB - PDF)

**First published:**

16/04/2025

[View](/fr/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (48.25 KB - PDF)

**First published:**

16/04/2025

[View](/hr/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (48.88 KB - PDF)

**First published:**

16/04/2025

[View](/is/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_is.pdf)

italiano (IT) (46.62 KB - PDF)

**First published:**

16/04/2025

[View](/it/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (49.82 KB - PDF)

**First published:**

16/04/2025

[View](/lv/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (50.07 KB - PDF)

**First published:**

16/04/2025

[View](/lt/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (51.45 KB - PDF)

**First published:**

16/04/2025

[View](/hu/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (49.17 KB - PDF)

**First published:**

16/04/2025

[View](/mt/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (48.07 KB - PDF)

**First published:**

16/04/2025

[View](/nl/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (51.31 KB - PDF)

**First published:**

16/04/2025

[View](/no/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_no.pdf)

polski (PL) (50.99 KB - PDF)

**First published:**

16/04/2025

[View](/pl/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_pl.pdf)

português (PT) (68.02 KB - PDF)

**First published:**

16/04/2025

[View](/pt/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_pt.pdf)

română (RO) (48.87 KB - PDF)

**First published:**

16/04/2025

[View](/ro/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (50.6 KB - PDF)

**First published:**

16/04/2025

[View](/sk/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (48.73 KB - PDF)

**First published:**

16/04/2025

[View](/sl/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (44.91 KB - PDF)

**First published:**

16/04/2025

[View](/fi/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (48.64 KB - PDF)

**First published:**

16/04/2025

[View](/sv/documents/all-authorised-presentations/dyrupeg-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Dyrupeg Active substance pegfilgrastim International non-proprietary name (INN) or common name pegfilgrastim Therapeutic area (MeSH)

- Neutropenia
- Cancer

Anatomical therapeutic chemical (ATC) code L03AA13

### Pharmacotherapeutic group

Immunostimulants

### Therapeutic indication

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

## Authorisation details

EMA product number EMEA/H/C/006407

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

CuraTeQ Biologics s.r.o

Trtinova 260/1 Cakovice 196 00 Prague-Cakovice Czechia

Opinion adopted 30/01/2025 Marketing authorisation issued 28/03/2025 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Dyrupeg : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (238.86 KB - PDF)

**First published:** 12/08/2025

[View](/en/documents/procedural-steps-after/dyrupeg-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Dyrupeg : EPAR -  Procedural steps taken and scientific information after authorisation (archive)

English (EN) (140.27 KB - PDF)

**First published:** 25/04/2025

**Last updated:** 13/05/2025

[View](/en/documents/procedural-steps-after/dyrupeg-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Dyrupeg : EPAR - Public assessment report

Adopted

Reference Number: EMA/57953/2025

English (EN) (4.44 MB - PDF)

**First published:** 16/04/2025

[View](/en/documents/assessment-report/dyrupeg-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Dyrupeg

Adopted

Reference Number: EMA/24523/2025

English (EN) (121.96 KB - PDF)

**First published:** 31/01/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-dyrupeg_en.pdf)

#### News on Dyrupeg

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2025) 31/01/2025

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Dyrupeg : EPAR - Product information - tracked changes

English (EN) (953.62 KB - DOCX)

**First published:** 25/04/2025

**Last updated:** 12/08/2025

[View](/en/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-733)

български (BG) (874.74 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/bg/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_bg.docx)

español (ES) (932.74 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/es/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_es.docx)

čeština (CS) (859.46 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/cs/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (863.38 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/da/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (857.73 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/de/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (908.89 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/et/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (869.92 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/el/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_el.docx)

français (FR) (869.93 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/fr/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (599.92 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/hr/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (1.07 MB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/is/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_is.docx)

italiano (IT) (854.17 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/it/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (918.71 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/lv/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (920.79 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/lt/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (873.4 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/hu/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (863.49 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/mt/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (866.23 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/nl/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (846.52 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/no/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_no.docx)

polski (PL) (853.77 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/pl/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_pl.docx)

português (PT) (931.1 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/pt/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_pt.docx)

română (RO) (909.18 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/ro/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (768.41 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/sk/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (935.41 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/sl/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (842.2 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/fi/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (850.02 KB - DOCX)

**First published:**

25/04/2025

**Last updated:**

13/05/2025

[View](/sv/documents/product-information-tracked-changes/dyrupeg-epar-product-information-tracked-changes_sv.docx)

**This page was last updated on** 12/08/2025

## Share this page

[Back to top](#main-content)